Glenmark’s GBR 500 enters Phase II clinical development

13 Sep 2012 Evaluate

Glenmark Pharmaceuticals (GPL) - wholly owned subsidiary - Glenmark Pharmaceuticals S.A. (GPSA), GBR 500 has entered Phase II clinical development. This Phase II clinical trial is part of a strategic global collaboration between Glenmark and Sanofi to investigate GBR 500 for the treatment of chronic inflammatory disorders.

This study is a randomized, double-blind, placebo-controlled, multi-center designed to investigate the efficacy and safety of GBR 500 in patients with moderate to severe ulcerative colitis (UC). The trial will be conducted at multiple clinical sites in North America and Europe, and is expected to include approximately 84 patients. Individuals participating in the study will receive multiple doses of either GBR 500 or placebo, administered over a period of several weeks.

GBR 500 is an antagonist of the VLA2 (alpha2-betal) integrin. It is a first-in-class therapeutic monoclonal antibody for chronic autoimmune disorders. Glenmark has completed Phase 1 of GBR 500 in the US. Sanofi has licensed the rights to all therapeutic indications and is conducting the clinical development program including this trial.

Glenmark Pharma Share Price

1952.90 14.55 (0.75%)
10-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.25
Dr. Reddys Lab 1251.10
Cipla 1489.15
Zydus Lifesciences 923.70
Lupin 2055.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×